LONDON, April 17, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Investor-Edge has initiated coverage on the following equities: Agenus Inc. (NASDAQ: AGEN), Raptor Pharmaceutical Corporation (NASDAQ: RPTP), KaloBios Pharmaceuticals Inc. (NASDAQ: KBIO), Amicus Therapeutics Inc. (NASDAQ: FOLD), and Sarepta Therapeutics Inc. (NASDAQ: SRPT). Free research report on Agenus can be accessed at http://get.Investor-Edge.com/pdf/?c=Agenus&d=17-Apr-2015&s=AGEN. On Thursday, April 16, 2015, the NASDAQ Composite ended at 5,007.79, down 0.06%, the Dow Jones Industrial Average lost 0.04%, to finish the day at 18,105.77, and the S&P 500 closed at 2,104.99, down 0.08%. The losses were broad based as seven out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 854.26, down 0.06%, while the index has advanced 4.87% in the previous three months. Register for your complimentary reports at the links given below.
On Thursday, shares in Agenus Inc. recorded a trading volume of 0.49 million shares, lower than its three months average volume of 1.10 million shares. The stock ended the day at $5.62, which was 1.08% above its previous day's closing of $5.56, and registered an intraday range of $5.52 and $5.65. Agenus Inc.'s shares have advanced 1.44% in the previous three trading sessions, 4.85% in the last one month and 133.20% in the past one year. The stock is trading above its 50-day and 200-day moving averages of $5.17 and $3.86, respectively. Furthermore, shares of Agenus Inc. have a Relative Strength Index (RSI) of 59.10. Sign up and read the free notes on AGEN at:
Raptor Pharmaceutical Corp.'s stock gained 1.20%, to close Thursday's session at $11.00, after oscillating between $10.61 and $11.01. The stock recorded a trading volume of 0.79 million shares, below its three months average volume of 1.33 million shares. Over the previous three trading sessions and the last three months, Raptor Pharmaceutical Corp.'s shares have advanced 3.97% and 10.11%, respectively. Additionally, the stock has surged 29.41% in the last one year. The company's shares are trading above their 50-day and 200-day moving averages. The stock's 50-day moving average of $10.44 is above its 200-day moving average of $10.09. Further, Raptor Pharmaceutical Corp.'s stock has an RSI of 51.06. The complimentary notes on RPTP can be downloaded as in PDF format at:
KaloBios Pharmaceuticals Inc.'s stock finished Thursday's session 8.75% higher at $0.58. A total of 0.70 million shares were traded, which was below its three months average volume of 1.25 million shares. The stock moved between $0.52 and $0.60 during the session. KaloBios Pharmaceuticals Inc.'s shares have surged 8.75% in the last one month and 21.35% in the previous three months. However, the stock has declined 75.58% in the past one year. The company's shares are trading above their 50-day moving average. Moreover, the stock's 200-day moving average of $1.33 is greater than its 50-day moving average of $0.51. KaloBios Pharmaceuticals Inc.'s stock has an RSI of 49.38. Register for free on Investor-Edge and access the latest research on KBIO at:
On Thursday, shares in Amicus Therapeutics Inc. fluctuated between $11.85 and $12.55 before ending the session 3.79% lower at $11.94. The stock reported a trading volume of 1.02 million shares, below its three months average volume of 1.80 million shares. Amicus Therapeutics Inc.'s shares have rallied 24.38% in the last one month, 46.32% in the previous three months and 556.04% in the past one year. The stock is trading above its 50-day and 200-day moving averages of $9.61 and $7.16, respectively. Moreover, shares of Amicus Therapeutics Inc. have an RSI of 71.44. The complete research on FOLD is available for free at:
Sarepta Therapeutics Inc.'s stock declined 2.43%, to close the day at $13.47. The stock recorded a trading volume of 0.64 million shares, below its three months average volume of 0.78 million shares. The stock oscillated between $13.43 and $13.92 during the session. Over the last three trading sessions and over the past one year, Sarepta Therapeutics Inc.'s shares have declined 1.54% and 44.41%, respectively. However, the stock has surged 11.23% in the previous three months. The company's shares are trading below their 50-day and 200-day moving averages. The stock's 200-day moving average of $17.56 is above its 50-day moving average of $13.72. Additionally, Sarepta Therapeutics Inc. has an RSI of 49.89. Free in depth research on SRPT is available at:
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.